Arcturus Therapeutics ARCT shares are trading higher on Monday after the company announced the completion of the first three dose escalation cohorts in Phase 1 study of its ARCT-810 for Ornithine Transcarbamylase Deficiency.
Arcturus Therapeutics is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-2020.
Arcturus Therapeutics shares traded up 13.03% to $48.36 on Monday. The stock has a 52-week high of $66.24 and a 52-week low of $8.51.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
